These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23558218)

  • 61. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease.
    Foley RN
    Rev Cardiovasc Med; 2005; 6 Suppl 3():S27-34. PubMed ID: 16340936
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Is there an optimal hematocrit value for cardiac patients?
    Cheng TO
    J Am Coll Cardiol; 2005 May; 45(9):1549; author reply 1550-1. PubMed ID: 15862436
    [No Abstract]   [Full Text] [Related]  

  • 63. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 65. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
    Iaina A; Silverberg DS; Wexler D
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):95-100. PubMed ID: 16265380
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".
    Belonje AM; de Boer RA; Voors AA
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):1-2. PubMed ID: 18219567
    [No Abstract]   [Full Text] [Related]  

  • 67. Treatment of anemia in chronic kidney disease--strategies based on evidence.
    Marsden PA
    N Engl J Med; 2009 Nov; 361(21):2089-90. PubMed ID: 19880845
    [No Abstract]   [Full Text] [Related]  

  • 68. Anemia associated with chronic heart failure: current concepts.
    Shah R; Agarwal AK
    Clin Interv Aging; 2013; 8():111-22. PubMed ID: 23403618
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V
    Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The anemia of heart failure.
    Silverberg DS; Wexler D; Palazzuoli A; Iaina A; Schwartz D
    Acta Haematol; 2009; 122(2-3):109-19. PubMed ID: 19907148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
    Jaspers A; Baron F; Maertens J; De Prijck B; Schots R; Bonnet C; Hafraoui K; Willems É; Servais S; Fillet G; Beguin Y
    Am J Hematol; 2015 Jul; 90(7):E133-4. PubMed ID: 25802012
    [No Abstract]   [Full Text] [Related]  

  • 73. On peginesatide and anemia treatment in CKD.
    Parfrey PS; Warden G; Barrett BJ
    Am J Kidney Dis; 2013 Oct; 62(4):659-61. PubMed ID: 23810692
    [No Abstract]   [Full Text] [Related]  

  • 74. Anemia and heart failure: Is there still a role for erythropoiesis-stimulating agents?
    Volpe M; Mastromariona V
    Turk Kardiyol Dern Ars; 2017 Apr; 45(3):217-218. PubMed ID: 28429688
    [No Abstract]   [Full Text] [Related]  

  • 75. Erythropoietin--not at the Olympics but maybe for anemic heart failure patients.
    SoRelle R
    Circulation; 2003 Jan; 107(2):e9004. PubMed ID: 12538444
    [No Abstract]   [Full Text] [Related]  

  • 76. Darbepoetin alfa in systolic heart failure.
    Silverberg DS; Schwartz D; Wexler D
    N Engl J Med; 2013 Aug; 369(5):487-8. PubMed ID: 23902506
    [No Abstract]   [Full Text] [Related]  

  • 77. Darbepoetin alfa in systolic heart failure.
    Karakas M; Koenig W
    N Engl J Med; 2013 Aug; 369(5):487. PubMed ID: 23902505
    [No Abstract]   [Full Text] [Related]  

  • 78. Darbepoetin alfa in systolic heart failure.
    Swedberg K; McMurray JJ; Young JB
    N Engl J Med; 2013 Aug; 369(5):488-9. PubMed ID: 23902504
    [No Abstract]   [Full Text] [Related]  

  • 79. Darbepoetin alfa in systolic heart failure.
    Farmakis D; Parissis J; Filippatos G
    N Engl J Med; 2013 Aug; 369(5):488. PubMed ID: 23902507
    [No Abstract]   [Full Text] [Related]  

  • 80. Are erythropoiesis-stimulating agents beneficial for anemia in chronic heart failure patients?
    Araneda D; Rada G
    Medwave; 2016 Nov; 16(Suppl5):e6607. PubMed ID: 27922585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.